Learn more about our product portfolio and how we're prioritising vaccines and specialty medicines to get ahead of disease together.
Our product areas
Our portfolio spans three product areas: vaccines, specialty products and targeted therapies and first-line products. We’re prioritising R&D investment in vaccines and specialty medicines, which we expect to grow to around three quarters of our business by 2026.
Our unrivalled vaccine portfolio targets infectious diseases at every stage of life. From adjuvants that improve vaccine effectiveness, through to mRNA technology, we use advanced technologies and collaborate with our partners to develop new, more effective vaccines that help people around the world to get ahead of disease.
Belgium is home to the core of GSK's Vaccines division, with three major production sites in Wavre, Rixensart and Gembloux, as well as the international operations centre. This represents the largest industrial vaccine production network in the world. Every day, more than 2 million doses of vaccine are produced in Belgium.
As our experts seek innovative new ways to treat the human body, specialty medicines are at the forefront of our high-value pipeline of new products. We are global leaders in developing medicines for respiratory disease and HIV, and we are building our presence in other therapeutic areas such as immunology and oncology. Specialty products are prescribed by healthcare professionals in so-called specialty therapeutic areas. For GSK, these include products in the areas of infectious diseases and severe asthma. In addition, we offer life-changing cancer drugs. In addition, we offer medicines for immune diseases, including the first new medicine for lupus, a chronic autoimmune disease from which several thousands of Belgian patients suffer.
First-line medicines are generally prescribed by general practitioners. At GSK, these include inhaled respiratory, dermatology and other diseases. These vital medications are the engine room for GSK, supporting hundreds of millions of people to enjoy a better everyday quality of life. For more than 50 years, we have been helping millions of people with respiratory conditions to breathe easier, including the first inhalers in 1969. GSK in Belgium, with its portfolio of respiratory treatments, remains the industry leader.
Our products in Belgium
You can find the complete list of our prescription medicines, vaccines and consumer healthcare products available in Belgium on the website of the Belgian Centre for Pharmacotherapeutic Information.
Following our joint venture agreement with Pfizer, we have created a new consumer healthcare and global pharmaceutical/vaccines company called Haleon.
Healthcare providers in Belgium can find specific information on our products available in Belgium by visiting www.gskpro.com.